Intrinsic Imaging Awarded Pivotal Phase II Clinical Trial Focused on Treatment of Degenerative Neuromuscular Disorder

Intrinsic Imaging was selected for this study due to its expertise and operational excellence in conducting musculoskeletal clinical trials.

Bolton, MA / San Antonio, TX

Bolton, MA / San Antonio, TX — September 12, 2017 — Intrinsic Imaging, a full-service medical imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials, announces today the award of a Phase II clinical trial for the evaluation of a novel biologic for the treatment of a rare degenerative neuromuscular disorder.

Intrinsic Imaging will provide its full suite of imaging core lab services for the duration of this trial. These services include study management, protocol and charter development, site qualification, training and management, image transfer, quality control and processing. Intrinsic Imaging will also perform all radiological reviews.

Intrinsic Imaging's team has extensive experience in providing services in support of Phase I-IV clinical trials and medical device trials involving musculoskeletal imaging. With its team of 10 full-time board-certified, fellowship-trained musculoskeletal radiologists, their expertise includes the full complement of joint and spine disease processes and musculoskeletal interventions including pain management and device. Their multiple modality expertise in musculoskeletal imaging includes, but is not limited to, ultrasound, nuclear imaging, DXA, MR, and CT including novel techniques such as QCT, T2 Cartilage imaging, MARS imaging and Kinetic MRI.

"Intrinsic Imaging was selected for this pivotal study due to our team's expertise and operational excellence in conducting musculoskeletal clinical trials," said Todd Joron, President and COO at Intrinsic Imaging. "We are excited to provide our expertise in the evaluation of this novel biologic and to help our partner further the development of their life altering treatment."

This trial will be conducted within Intrinsic Imaging's quality framework. With its portfolio of five ISO certifications, Intrinsic Imaging has the most comprehensive and most sophisticated quality management system in the industry.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 750 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com